Hydrobromides
Medchemexpress LLC Burixafor (hydrobromide) | 1191450-19-7 | 98.0% | 769.01 | 50 MG
Burixafor hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. It inhibits CXCL12 binding to CXCR4, antagonizes Gαᵢ and β-arrestin2 recruitment, and blocks downstream Gαᵢ-mediated effects on cAMP signal transduction. This compound mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist with a pIC50 of 7.4.
- Inhibits CXCL12 binding to CXCR4.
- Antagonizes CXCL12-induced Gαᵢ and β-arrestin2 recruitment.
- Blocks downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction.
- Mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC).
- Useful for research on autologous hematopoietic stem cell transplantation (ASCT).
Medchemexpress LLC Dihydro-β-erythroidine hydrobromide | 29734-68-7 | >98.0% | 356.25 g·mol⁻¹ | C16H22BrNO3 | 5 MG
Dihydro-β-erythroidine hydrobromide is a research reagent that acts as a competitive antagonist of neuronal nicotinic acetylcholine receptors, with preferential activity at α4β2 and α4β4 subtypes. Supplied as the hydrobromide salt, it is used in electrophysiology, receptor pharmacology, and in vivo studies to selectively inhibit nAChR-mediated responses.
- High purity (≥98% by HPLC).
- Selective antagonist for α4β2 and α4β4 nicotinic receptors.
- Suitable for in vitro and in vivo pharmacology studies.
- Supplied as hydrobromide salt for improved stability and solubility.
- Available in small research package sizes (1 mg, 5 mg, 10 mg).
- Documented identifiers include CAS 29734-68-7 and molecular weight 356.25 g·mol⁻¹.
eMolecules 180695-79-8 | N-Boc-4-bromopiperidine | ChemScene | MFCD04115039 | 264.163 | C10H18BrNO2 | 97.000 | CC(C)(C)OC(=O)N1CCC(Br)CC1 | 100g | 536842064
N-Boc-4-bromopiperidine | ChemScene | 180695-79-8 | MFCD04115039 | 264.163 | C10H18BrNO2 | 97.000 | CC(C)(C)OC(=O)N1CCC(Br)CC1 | 100g | 536842064
Medchemexpress LLC Pifithrin-α hydrobromide | 63208-82-2 | C16H19BrN2OS | 1 G
Pifithrin-α hydrobromide is a chemical compound known for its role as a p53 inhibitor, effectively blocking its transcriptional activity and preventing apoptosis in cells. Additionally, it functions as an aryl hydrocarbon receptor (AhR) agonist.
- Purity of 98.58%
- Appears as a solid, white to light yellow in color
- Recommended storage at 4°C, sealed and away from moisture; in solvent at -80°C for 6 months or -20°C for 1 month
- Soluble in DMSO at concentrations ≥ 50 mg/mL
- Targets p53 and aryl hydrocarbon receptor (AhR)
- Suppresses p53 protein transcription and inhibits p53-dependent apoptosis
- Acts as a potent AhR agonist, inducing DNA binding complex formation
Medchemexpress LLC Arecoline | 63-75-2 | 100 MG
Arecoline is a naturally brain-penetrant and orally active psychoactive alkaloid. It functions as a partial agonist of nicotinic and muscarinic acetylcholine receptors. It has been observed to exhibit stimulation, alertness, anxiolysis, and anti-parasitic effects. Research indicates it can also induce oxidative stress.
- Partial agonist of nicotinic and muscarinic acetylcholine receptors
- Exhibits stimulation and alertness
- Demonstrates anxiolysis and anti-parasitic effects
- Induces generation of reactive oxygen species
- Causes cell cycle arrest at G1/G0 phase in HaCaT cells
- Upregulates hemeoxygenase-1, ferritin light chain, glucose-6-phosphate dehydrogenase, glutamate-cysteine ligase catalytic subunit, and glutathione reductase expression
- Alleviates anxiety and depression in CFA-induced mice
Medchemexpress LLC Guvacoline hydrobrom 25mg | 17210-51-4 | 25 MG
Guvacoline hydrobromide is the hydrobromide salt of guvacoline, a pyridine alkaloid found in Areca triandra. It is used as a research reagent and functions as a weak full agonist of atrial and ileal muscarinic acetylcholine receptors (mAChR).
- Acts as a weak full agonist of atrial and ileal muscarinic receptors.
- White to off-white solid physical form.
- Molecular formula C7H12BrNO2 and molecular weight 222.08.
- Purity typically around 96.09% by HPLC.
- Store sealed at 4°C and protect from moisture and light; in solution store at -80°C for long-term.
- Supplied in small milligram pack sizes for laboratory research.
Medchemexpress LLC (RS)-AMPA hydrobromide | 171259-81-7 | MFCD00055183 | 99.5% | 267.08 g·mol⁻¹ | C7H11BrN2O4 | 5 MG
(RS)-AMPA hydrobromide is a research-grade glutamate analogue that acts as a potent, selective agonist of AMPA-type ionotropic glutamate receptors. Supplied as a solid hydrobromide salt with high purity, it is intended for use in neuropharmacology, electrophysiology, and receptor pharmacology studies. The compound is soluble in DMSO and water (sonication recommended) and should be stored protected from moisture under refrigerated or low-temperature conditions as specified by the supplier.
- Potent, selective agonist of AMPA receptors.
- Hydrobromide salt increases aqueous solubility.
- High purity suitable for research and analytical applications.
- Soluble in DMSO and water; sonication recommended.
- Stable when stored sealed and protected from moisture.
- Provided in small milligram quantities for experimental use.
eMolecules 180695-79-8 | N-Boc-4-bromopiperidine | ChemScene | MFCD04115039 | 264.163 | C10H18BrNO2 | 97.000 | CC(C)(C)OC(=O)N1CCC(Br)CC1 | 1g | 894452969
N-Boc-4-bromopiperidine | ChemScene | 180695-79-8 | MFCD04115039 | 264.163 | C10H18BrNO2 | 97.000 | CC(C)(C)OC(=O)N1CCC(Br)CC1 | 1g | 894452969
Apexbio Technology LLC SR 95531 hydrobromide 104104-50-9 5mg
SR 95531 hydrobromide (CAS 104104-50-9) also known as Gabazine is a selective competitive antagonist of the GABAA receptor By binding to the GABA recognition site on the receptor it blocks the activation induced by -aminobutyric acid (GABA) Experimental studies report an inhibitory concentration (IC50) of approximately 0 2 M for GABAA receptor-mediated responses Widely utilized in neuroscience research Gabazine is applied to investigate the physiological and pathological roles of GABAA receptor-mediated synaptic transmission neural network modulation and neurotransmitter regulation
Medchemexpress LLC Amthamine dihydrobromide | 142457-00-9 | MFCD00673891 | 99.6% | 319.07 g·mol⁻¹ | C6H13Br2N3S | 5 MG
Amthamine dihydrobromide is the dihydrobromide salt of amthamine, a selective histamine receptor agonist used in pharmacology and receptor research. It is supplied as a purified solid for use in in vitro and in vivo assays to probe histamine receptor function and signaling.
- High reported purity: 99.6%.
- Molecular weight 319.07 g·mol⁻¹.
- Supplied as a solid dihydrobromide salt.
- Suitable for histamine receptor pharmacology and assay work.
- Available in small milligram pack sizes for research use.
Apexbio Technology LLC NAN-190 hydrobromide 115338-32-4 200mg
NAN-190 hydrobromide (CAS 115338-32-4) is a selective antagonist of the serotonin 5-HT1A receptor functioning by inhibiting receptor-mediated signal transduction pathways In receptor binding assays NAN-190 hydrobromide demonstrates high affinity for 5-HT1A receptors and modulates neurotransmitter release This compound is frequently employed in neurobiology and psychiatric disorder studies to investigate 5-HT1A-related mechanisms serving as a valuable tool for elucidating serotonergic signaling and its implications in neural function and pathology
Medchemexpress LLC Pifithrin-β hydrobromide | 511296-88-1 | 100.0% | 349.29 | 50 MG
Pifithrin-β hydrobromide, also known as PFT β hydrobromide, is a potent p53 inhibitor with an IC50 of 23 μM. It is related to Pifithrin-α, a lead compound for cancer and neurodegenerative disease therapy, which rapidly converts to Pifithrin-β, its N-acetyl derivative. Pretreatment with 1 and 10 μM pifithrin-β has shown neuroprotective effects.
- Potent p53 inhibitor
- Exerts neuroprotective effects
- Used in cancer and neurodegenerative disease research
Medchemexpress LLC Halofuginone hydrobromide | 64924-67-0 | 495.59 | 50 MG
Halofuginone hydrobromide (Standard) is an analytical standard derived from Febrifugine, functioning as a competitive prolyl-tRNA synthetase inhibitor. It also acts as a specific inhibitor of type-I collagen synthesis, reducing osteoarthritis symptoms by suppressing TGF-β activity. Additionally, it is a potent pulmonary vasodilator, enhancing Kv channels and blocking various calcium channels, and is commonly used in qualitative, quantitative, and methodological research experiments.
- Intended for research and analytical applications
- Attenuates osteoarthritis
- Activates Kv channels
- Blocks voltage-gated, receptor-operated, and store-operated calcium channels
- Has anti-malaria effects
- Has anti-inflammatory effects
- Has anti-cancer effects
- Has anti-fibrosis effects
- Used in HPLC, GC, and MS research
Medchemexpress LLC CCT031374 hydrobromide | 1219184-91-4 | 98.1% | 434.33 | 100 MG
CCT 031374 hydrobromide is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. It inhibits TCF-dependent transcription of genes in the Wnt signaling pathway and exhibits antitumor activity.
- Potent inhibitor of β-catenin/transcription factor (TCF) complex signaling.
- Inhibits TCF-dependent transcription of genes of Wnt signaling pathway.
- Has antitumor activity.
- For research use only.
Apexbio Technology LLC 6-Hydroxydopamine hydrobromide(Synonyms: Oxidopamine hydrobromide, 6-OHDA hydrobromide, 6-Hydroxydopamine HBr), 50mg, CAS: 636-00-0.
6-Hydroxydopamine hydrobromide (CAS 636-00-0) commonly referred to as 6-OHDA hydrobromide is a catecholamine-derived neurotoxin frequently used in neuroscience research to induce selective dopaminergic neuronal degeneration Upon administration it generates intracellular reactive oxygen species (ROS) activating apoptotic pathways via caspase-3 -8 and -9 as demonstrated in PC12 cell studies In rodent models targeted injection into substantia nigra striatum or medial forebrain bundle leads to loss of tyrosine hydroxylase-positive neurons and resultant locomotor dysfunction resembling symptoms observed in Parkinson s disease Consequently it serves as a valuable tool for elucidating dopaminergic dysfunction mechanisms and evaluating therapeutic candidates